Back to News
Market Impact: 0.25
aTyr Pharma Consensus Price Target Increased by 3,900.04% to $115.60
Source: Nasdaq
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Fintel reported that the average one-year analyst price target for aTyr Pharma was revised to $115.60 per share, up 3,900.04% from $2.89 on October 20, 2026. The figures are aggregated analyst targets; the article provides no explanation for the revision or reported market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ATYR0.20
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?